A signal amplification method for the simultaneous detection of respiratory RNA viruses in complex samples. The combination of molecular beacon technology and enzymatic digestion has proved to be a highly specific, cost-effective and fast alternative for detecting viral pathogens.
Novel polysaccharides that are effective in treatment and prevention of viral infections. These compounds are mimics of heparan sulfates present in cells. They act as decoy trap preventing the virus from adhering to epithelial cells, thus slowing down the process of infection.
Two different vaccines prototypes have been developed based on RNA replicons from SARS-CoV-2 and MERS-CoV, encapsulated in Virus-Like Particles (VLPs), which can be used as a vaccines to generate immunity and protect against infections by these coronavirus.
A panel of high affinity nanobodies (Nb) binding to diverse SARS-CoV-2 RBD epitopes of spike protein, and a set of nanobody-derived neutralizing heavy chain antibodies (hcAbs) have been identified. They have potential as therapy against SRAS-CoV-2 for immunocompromised or non-responding to vaccines individuals.
New family of molecules with potent and selective antiviral activity in cellular models of infection by various coronaviruses such as SARS-CoV-2, MERS-CoV, hCoV-229E. They do not show cytotoxicity or activity against other viruses with RNA genome such as West Nile fever virus, dengue virus and vesicular stomatitis virus at relevant doses.
Immunochemical method for diagnosis of infections produced by Pseudomonas aeruginosa targeting the main signalling molecules of the pqs Quorum Sensing system. The immunoassay is fast and efficient, with low LOD and adaptable to point-of-care devices.